| pubmed-article:21665462 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C0920317 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C0023413 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:21665462 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:21665462 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:21665462 | pubmed:dateCreated | 2011-8-8 | lld:pubmed |
| pubmed-article:21665462 | pubmed:abstractText | Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5-fluorouracil or alone in patients previously treated with a fluoropyrimidine. We compared toxicity (particularly diarrhoea), quality of life, and efficacy of combination chemotherapy and irinotecan in these patients. | lld:pubmed |
| pubmed-article:21665462 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21665462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21665462 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21665462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21665462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21665462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21665462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21665462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21665462 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21665462 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:21665462 | pubmed:issn | 1879-0852 | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:SimesR JohnRJ | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:BuckMartinM | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:BrownChrisC | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:GoldsteinDavi... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:ZalcbergJohnJ | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:ClarkeStephen... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:GebskiValV | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:TebbuttNiall... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:LowenthalRaym... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:JeffreyG... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:Australasian... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:YipSoniaS | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:RansomDavid... | lld:pubmed |
| pubmed-article:21665462 | pubmed:author | pubmed-author:BolandAmyA | lld:pubmed |
| pubmed-article:21665462 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21665462 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21665462 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:21665462 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21665462 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21665462 | pubmed:pagination | 1826-36 | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:meshHeading | pubmed-meshheading:21665462... | lld:pubmed |
| pubmed-article:21665462 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21665462 | pubmed:articleTitle | Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. | lld:pubmed |
| pubmed-article:21665462 | pubmed:affiliation | Department of Medicine, Concord Hospital, Concord, Sydney, Australia. stephen.clarke@sydney.edu.au | lld:pubmed |
| pubmed-article:21665462 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21665462 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21665462 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21665462 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:21665462 | pubmed:publicationType | Meta-Analysis | lld:pubmed |
